Table II.

Treatment characteristics of the study group of polycystic ovary syndrome (PCOS) women.

	Women with PCOS (n = 15 106)
Hyperandrogenic status
Normo-androgenic PCOS women	7157 (47.4%)
Hyperandrogenic PCOS women	7949 (52.6%)
Combinations of aa medications used
No anti-androgenic medications	7157 (47.4%)
aaCOCs only	5456 (36.1%)
aaCOCs and plain anti-androgens combined	1533 (10.1%)
Plain anti-androgens only	960 (6.4%)
Hyperandrogenic status
Normo-androgenic PCOS women	7157 (47.4%)
Mildly hyperandrogenic PCOS women	5456 (36.1%)
Severely hyperandrogenic PCOS women	2493 (16.5%)
Timing of any anti-androgenic medications**
Early users	2276 (15.1%)
Late users	5673 (37.6%)
Non users	7157 (47.4%)
aaCOCs
Early users	1939 (12.8%)
Late users	5050 (33.4%)
Non users	8117 (53.7%)
Plain anti-androgens
Early users	514 (3.4%)
Late users	1979 (13.1%)
Non users	12 613 (83.5%)

^**Early and late users comprise PCOS women with anti-androgenic treatment initiated up to or above 18 years of age, respectively.

aaCOCs, anti-androgenic combined oral contraceptives.

Data are presented as n (%).